ReviewAsian journal of pharmaceutical sciences2025
Recent advances in cell membrane-based biomimetic delivery systems for Parkinson's disease: Perspectives and challenges.
Review in Asian journal of pharmaceutical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- From neuroinflammation to immune reprogramming: Nanozyme-Integrated nanoplatforms for neuroimmune modulation in Parkinson's disease.Materials today. Bio · 2026Article
- Lipid Composition Determines Hybrid Nanoparticle Selectivity: Beyond Membrane Mimicry in Cancer Targeting.Nano letters · 2026Article
- Multifunctional Hybrid Nanomedicines for Neurodegenerative Diseases: A Paradigm Shift from Rational Design to Clinical Translation.International journal of nanomedicine · 2026Review
- Organelle-Targeted Nanotherapeutics for Parkinson's Disease: From Pathogenesis to Preclinical Strategies and Translational Challenges.International journal of nanomedicine · 2026Review
- Cell Membrane- and Vesicle-Based Bionic Nanodrugs: Applications in Central Nervous System Diseases and Exploration of Nasal-Cerebral Delivery.Gels (Basel, Switzerland) · 2025Review
- Top-down engineered micron-cell derived nanovesicles encapsulating curcumin targeting the 3R strategy (remove, remodel, repair) for Alzheimer's disease therapy.Materials today. Bio · 2025Article
- Nanoparticles: a new frontier in neurodegenerative disease therapy.Frontiers in medical technology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroinflammation, α-synuclein pathology and dopaminergic cell loss are the hallmarks of Parkinson's disease (PD), an incurable movement disorder. The presence of the blood-brain barrier (BBB) impedes the delivery of therapeutics and makes the design of drug-targeting delivery vehicles challenging. Nanomedicine is designed and has significantly impacted the scientific community. Over the last few decades, to address the shortcomings of synthetic nanoparticles, a new approach has emerged that mimic the physiological environment. Cell membrane-coated nanoparticles have been developed to interact with the physiological environment, enhance central nervous system drug delivery and mask toxic effects. Cell membranes are multifunctional, biocompatible platforms with the potential for surface modification and targeted delivery design. A synchronous design of cell membrane and nanoparticles is required for the cell membrane-based biomimetics, which can improve the BBB recognition and transport. This review summarizes the challenges in drug delivery and how cell membrane-coated nanoparticles can overcome them. Moreover, major cell membranes used in biomedical applications are discussed with a focus on PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.